419 related articles for article (PubMed ID: 18042483)
1. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
Hillner BE; Schrag D; Sargent DJ; Fuchs CS; Goldberg RM
Cancer; 2005 Nov; 104(9):1871-84. PubMed ID: 16177989
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
Hurwitz HI; Fehrenbacher L; Hainsworth JD; Heim W; Berlin J; Holmgren E; Hambleton J; Novotny WF; Kabbinavar F
J Clin Oncol; 2005 May; 23(15):3502-8. PubMed ID: 15908660
[TBL] [Abstract][Full Text] [Related]
4. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
5. New systemic frontline treatment for metastatic colorectal carcinoma.
Braun AH; Achterrath W; Wilke H; Vanhoefer U; Harstrick A; Preusser P
Cancer; 2004 Apr; 100(8):1558-77. PubMed ID: 15073842
[TBL] [Abstract][Full Text] [Related]
6. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
Kashiwa M; Matsushita R
Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
[TBL] [Abstract][Full Text] [Related]
7. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S
J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Treatment Sequences of Chemotherapies and Targeted Biologics for Elderly Metastatic Colorectal Cancer Patients.
Parikh RC; Du XL; Robert MO; Lairson DR
J Manag Care Spec Pharm; 2017 Jan; 23(1):64-73. PubMed ID: 28025930
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.
Giantonio BJ
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S15-8. PubMed ID: 17145520
[TBL] [Abstract][Full Text] [Related]
10. The future development of bevacizumab in colorectal cancer.
Díaz-Rubio E; Schmoll HJ
Oncology; 2005; 69 Suppl 3():34-45. PubMed ID: 16301834
[TBL] [Abstract][Full Text] [Related]
11. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.
Chen HX; Mooney M; Boron M; Vena D; Mosby K; Grochow L; Jaffe C; Rubinstein L; Zwiebel J; Kaplan RS
J Clin Oncol; 2006 Jul; 24(21):3354-60. PubMed ID: 16849749
[TBL] [Abstract][Full Text] [Related]
12. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.
Hurwitz H
Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S62-8. PubMed ID: 15479481
[TBL] [Abstract][Full Text] [Related]
13. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Kabbinavar FF; Schulz J; McCleod M; Patel T; Hamm JT; Hecht JR; Mass R; Perrou B; Nelson B; Novotny WF
J Clin Oncol; 2005 Jun; 23(16):3697-705. PubMed ID: 15738537
[TBL] [Abstract][Full Text] [Related]
14. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
15. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
J Clin Oncol; 2015 Apr; 33(10):1112-8. PubMed ID: 25691669
[TBL] [Abstract][Full Text] [Related]
16. The role of bevacizumab as first-line therapy for colon cancer.
Marshall J
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S43-7. PubMed ID: 16399431
[TBL] [Abstract][Full Text] [Related]
17. Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.
Tse VC; Ng WT; Lee V; Lee AW; Chua DT; Chau J; McGhee SM
BMC Cancer; 2011 Jul; 11():288. PubMed ID: 21740590
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
Hurwitz H; Kabbinavar F
Oncology; 2005; 69 Suppl 3():17-24. PubMed ID: 16301832
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of FOLFIRI-Based First-Line Regimens for Metastatic Colorectal Cancer Using Clinical Decision Analysis.
Shida T; Ono Y; Kobayashi Y; Ogura J; Hatakeyama S; Arakawa I; Inoue T; Yamaguchi H
Gan To Kagaku Ryoho; 2024 May; 51(5):541-547. PubMed ID: 38881065
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis.
Norum J
J Chemother; 2006 Oct; 18(5):532-7. PubMed ID: 17127231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]